Latest in Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027

Find out more

You need to be a subscriber to read this article.
Click here to find out more.

From box to bedside: unlocking patient-centric care with connected packaging

Pharmaceutical packaging is playing an increasing role in patient–centric care. The integration of smart 2D codes and connected digital platforms can provide a direct link...
See more

New CGT centre in Bangkok to boost Southeast Asia’s biotech ecosystem

eXmoor Pharma and Siam Bioscience form a strategic partnership to establish leading cell and gene therapy services in Southeast Asia

Pfizer to acquire Metsera in $4.9bn deal, expanding obesity drug pipeline with next-generation incretin and amylin therapies

The deal strengthens Pfizer’s position in the fast-growing obesity market, with additional milestone payments of up to $2.3bn tied to key clinical and regulatory achievements

DaltonTx secures £4m in seed financing to build adaptive, AI-enabled discovery platforms

The UK-based technology company's adaptive platform will plug directly into pharma, biotech and CRO workflows, giving teams instant access to AI-enabled discovery

Prange Pharma to acquire MSD Animal Health manufacturing site in Aprilia, Italy

Following completion, the site will relaunch as Aprilia Animal Health, focussing on contract manufacturing of animal health products whilst preserving jobs and expanding European expertise

EMV Capital subsidiary Moirai acquires Destiny Pharma’s XF-73 antibiotic platform

The XF drug platform, designed to prevent bacterial resistance and combat Gram-positive infections such as MRSA, represents a high-impact addition to EMV’s life sciences portfolio

ScaleReady awards nearly $2m in G-Rex grants to advance cell and gene therapy manufacturing in California

The initiative supports leading academic GMP facilities in developing scalable, cost-effective platforms for CAR-T and other cell therapies, reinforcing California’s position as a global hub for CGT innovation

Bio Protocol raises $6.9m to launch AI-powered decentralised science platform

The new platform enables researchers and patients to create "BioAgents" — autonomous AI co-scientists — to bring a faster, blockchain-verified path from lab to market

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced

Latest posts in Finance

AecorBio raises $1.5m at $30m valuation to advance investigational studies of its novel prostate cancer peptide FT-002a

The financing will support preparations for a 2026 FDA Investigational New Drug (IND) application, paving the way for clinical development of the co-therapy designed to restore iron metabolism and boost treatment response

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France

Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables

Simris Biologics secures €200K funding to develop microcystin-based payloads for antibody-drug conjugates

The Berlin-based subsidiary will use the grant to advance the KlicMic R&D programme, creating targeted microcystin payloads for ADCs that aim to improve cancer therapy efficacy whilst reducing side effects

Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness

The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production

Almac expands bioavailability capabilities to address a critical need in drug development

Almac Group has completed a multimillion-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK

Fidia Farmaceutici enters the UK market with the acquisition of Altacor

Marking another significant milestone in its ongoing international expansion, the company enters the rapidly growing UK ophthalmology market, a key therapeutic area for the group

SGD Pharma acquires Alphial Srl in a strategic step forward

SGD Pharma is pleased to announce an agreement with Italian Private Equity firm Entangled Capital to acquire Alphial Srl, a leading producer of tubular vials and ampoules headquartered in Italy

Piramal and NewAmsterdam Pharma invest in a dedicated suite to enhance oral solid dosage production

The multimillion-dollar investment provides NewAmsterdam Pharma with the commercial capacity to produce a fixed-dose combination (FDC) of obicetrapib and ezetimibe to meet commercial demand

RedHill Biopharma awarded $1.8m in legal costs and expenses by New York Supreme Court

The New York Supreme Court has awarded RedHill $1.82m in legal costs and expenses, in addition to the prior summary judgment of $8.25m, in its action against Kukbo Co. Ltd

Upperton Pharma Solutions advances oral vaccine delivery with Oxford’s Pandemic Sciences Institute

Upperton Pharma Solutions has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford

Sponsor content

GEA raises guidance following strong H1 performance

Revised forecast reflects improved margins, robust order intake and efficiency gains

Lonza delivers strong H1 2025 performance

Lonza delivers strong H1 2025 performance and upgrades 2025 full-year CDMO sales and margin outlook

Gerresheimer reports H1 2025 growth driven by Bormioli Pharma acquisition

Cosmetics and oral liquids markets dampen organic revenue but outlook remains strong

Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon

Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in...

CARBOGEN AMCIS accelerates manufacturing capacity with CHF 25.5 million co-investment at Swiss sites

CARBOGEN AMCIS is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at...

Gerresheimer adjusts guidance for Financial Year 2025

Gerresheimer is adjusting its guidance for 2025 due to continuing subdued demand in the cosmetics market and a decline in demand for plastic containment solutions for oral...

Almac Group hits record £1 billion revenue milestone

Strong financials support expansion in manufacturing and clinical capabilities

Lonza publishes updated 2024 financials ahead of One Lonza reporting

New CDMO platform structure supports upcoming half-year 2025 results

Vetter once again named best managed company

The award jury recognises strategic and sustainable corporate management

SCHOTT Pharma delivers strong second quarter of fiscal year 2025

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 2025

Gerresheimer: Bormioli Pharma boosts revenues and earnings

Gerresheimer recorded a jump in revenues and earnings due to the first-time consolidation of Bormioli Pharma, which was acquired in 2024

Piramal Pharma Limited announces results for Q3 and 9M FY25

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Months (9M) ended 31st December...